BioFactura Joins Stelara Biosimilar Crowd
US-Based Developer Throws Its Hat Into The Ring For Ustekinumab
Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.
You may also be interested in...
California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.
BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill.
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.